<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448201</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 0306</org_study_id>
    <secondary_id>P30CA016086</secondary_id>
    <nct_id>NCT00448201</nct_id>
  </id_info>
  <brief_title>Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease</brief_title>
  <official_title>Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor
      stem cell transplant helps stop the growth of cancer and abnormal cells. It also helps stop
      the patient's immune system from rejecting the donor's stem cells. The donated stem cells may
      replace the patient's immune cells and help destroy any remaining cancer or abnormal cells
      (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an
      immune response against the body's normal cells. Immunosuppressive therapy may improve bone
      marrow function and may be an effective treatment for hematologic cancer or other disease.

      PURPOSE: This clinical trial is studying the side effects and how well giving busulfan and
      fludarabine with or without antithymocyte globulin followed by donor stem cell transplant
      works in treating patients with hematologic cancer or other disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the clinical efficacy and toxicity profiles of a nonmyeloablative preparative
           regimen comprising busulfan and fludarabine with or without anti-thymocyte globulin
           followed by allogeneic hematopoietic stem cell transplantation in patients with
           hematologic cancers or other diseases.

        -  Determine the feasibility of this regimen in these patients.

        -  Establish a treatment-related mortality during the first 6 months that is less than 20%
           in patients treated with this regimen.

      Secondary

        -  Determine the response rates (disease-specific partial response and complete response)
           in patients treated with this regimen.

        -  Determine overall and progression-free survival of patients treated with this regimen.

        -  Determine the percent donor chimerism and immunologic recovery, including dendritic cell
           recovery, in patients treated with this regimen.

        -  Determine the risk of acute and chronic graft-versus-host disease and other toxicities
           in patients treated with this regimen.

        -  Assess the overall nonhematologic grades 3 and 4 toxicity of this regimen, including the
           incidence of veno-occlusive disease and pulmonary toxicity, in these patients.

      OUTLINE: Patients are assigned to 1 of 4 treatment groups according to disease type and donor
      type.

        -  Preparative regimen:

             -  Group 1 (patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia
                (ALL), IPSS (International Prognostic Scoring System score) high-risk
                myelodysplastic syndromes (HR MDS), or chronic myelogenous leukemia (CML) with an
                human leukocyte antigen (HLA)-matched related donor (MRD): Patients receive
                fludarabine phosphate IV over 30 minutes on days -7 to -3 and busulfan IV
                continuously over 48 hours on days -6 and -5.

             -  Group 2 (patients with AML, ALL, IPSS HR MDS, or CML with an HLA-matched unrelated
                donor (MUD) or mismatched related donor (MMRD)): Patients receive fludarabine
                phosphate and busulfan as in group 1 and anti-thymocyte globulin IV over 4 hours on
                day -8.

             -  Group 3 (patients with all other diseases with a MRD): Patients receive fludarabine
                phosphate and busulfan as in group 1 and anti-thymocyte globulin as in group 2.

             -  Group 4 (patients with all other disease with a MUD or MMRD): Patients receive
                fludarabine phosphate and busulfan as in group 1 and anti-thymocyte globulin IV
                over 4 hours on days -8 and -7.

        -  Allogeneic stem cell transplantation: All patients undergo allogeneic peripheral blood
           stem cell transplantation on day 0. Patients then receive sargramostim (GM-CSF)
           subcutaneously once daily beginning on day 5 (groups 1 and 2) or day 7 (groups 3 and 4)
           and continuing until blood counts recover.

        -  Graft-vs-host disease (GVHD) prophylaxis: All patients receive oral tacrolimus twice
           daily on days -1 to 120 followed by a taper until day 180. Patients in groups 1 and 2
           also receive methotrexate IV on days 1, 3, and 6.

        -  Donor lymphocyte infusion (DLI): After day 120, patients with progressive disease or
           stable disease while off immunosuppression and with no evidence of active GVHD may
           receive DLI. Treatment with DLI may repeat every 8 weeks for up to 3 total infusions in
           the absence of disease response or GVHD.

      Peripheral blood and/or bone marrow samples are collected at baseline and then at 30, 60, 90,
      120, and 180 days post-transplantation. Chimerism (including the following subsets: whole
      blood, T-cells as defined by cluster of differentiation 3 (CD3) positivity, B-cells as
      defined by Cluster of Differentiation 19 (CD19) positivity, and myeloid cells as defined by
      Cluster of Differentiation 14 (CD14) and Cluster of Differentiation 15 (CD15) positivity is
      analyzed by polymerase chain reaction technology.

      After restaging between Days 90 and 100 and between Days 150 to 180, patients are followed
      every 6 months for 1 years and then yearly for a maximum of 5 years from study entry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2011</start_date>
  <completion_date type="Actual">May 23, 2012</completion_date>
  <primary_completion_date type="Actual">January 11, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related Mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Treatment related mortality for first 6 months. Defined as the number of treatment related deaths excluding deaths due to disease relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response at 6 and 12 Months Post-transplant</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete or Mixed Donor Chimerism at 30, 60, and 90 Days Post-transplant</measure>
    <time_frame>Days 30, 60, and 90</time_frame>
    <description>Complete chimerism is defined as 100% donor cells detected, suggesting complete hematopoietic replacement. Mixed donor chimerism means host cells are detected in particular cells like lymphocytes. Five to 90% donor cells set the criteria for mixed chimerism (MC).
Chimerism was not tabulated on day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year Disease-free Survival</measure>
    <time_frame>Year 5</time_frame>
    <description>The length of time post-transplant that the patient survives without any signs or symptoms of that cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-vs-host Disease at 6 Months Post-transplant</measure>
    <time_frame>6 Months</time_frame>
    <description>Graft-vs-host disease (GVHD) can be mild, moderate or severe depending on the differences in tissue type between patient and donor. Its symptoms can include:
Rashes, which include burning and redness, that erupt on the palms or soles and may spread to the trunk and eventually to the entire body
Blistering, causing the exposed skin surface to flake off in severe cases
Nausea, vomiting, abdominal cramps, diarrhea and loss of appetite, which can indicate that the gastrointestinal (digestive) tract is affected
Jaundice, or a yellowing of the skin, which can indicate liver damage
Excessive dryness of the mouth and throat, leading to ulcers
Dryness of the lungs, vagina and other surfaces
Acute GVHD - Can occur soon after the transplanted cells begin to appear in the recipient. Acute GVHD ranges from mild, moderate or severe, and can be life-threatening if its effects are not controlled.
Extensive chronic GVHD - Usually occurs at about three months post-transplant.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GVHD Prophylaxis with Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GVHD prophylaxis with antithymocyte globulin (ATG) + Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GVHD prophylaxis with 2 doses ATG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Doses ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GVHD prophylaxis with 3 doses ATG</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)</description>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>GM-CSF 500 ug everyday (QD) subcutaneously will be given to recipients who remain with an Absolute neutrophil count (ANC) &lt; 1000/microliter (uL) past day 20</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <description>A minimum total cluster of differentiation 34 (CD34)+ cell dose of 3 x 10^6 cells/kg and a maximum 8 x 10^6 cells/kg will be infused on day 0</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>fludarabine 30 mg/m^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Methotrexate 5 mg/m^2 per day on days +1, +3 and +6</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Suggested starting dose is 0.03 mg/kg po bid starting on Day -1</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Chronic lymphocytic leukemia (CLL), meeting the following criteria:

                    -  Absolute lymphocyte count &gt; 5,000/mm³

                    -  Lymphocytes must appear morphologically mature with &lt; 55% prolymphocytes

                    -  Lymphocyte phenotype with expression of CD19 and cluster of differentiation
                       5 (CD5)

               -  Prolymphocytic leukemia (PLL), meeting the following criteria:

                    -  Absolute lymphocyte count &gt; 5,000/mm³

                    -  More than 55% prolymphocytes

                    -  Morphologically diagnosed

               -  Chronic myelogenous leukemia (CML), meeting the following criteria:

                    -  Diagnosis of CML or similar myeloproliferative disorders based on t(9;22) or
                       related t(9;12) cytogenetic abnormalities AND characterized by elevated
                       white blood cell (WBC) counts in peripheral blood or bone marrow

                    -  In first chronic phase CML and a candidate for treatment with reduced-dose
                       busulfan

                    -  Patients with other cytogenetic abnormalities, such as t(9;12), that are
                       associated with an aggressive clinical course are eligible

               -  Non-Hodgkin's lymphoma (NHL), meeting the following criteria:

                    -  Any World Health Organization (WHO) class histologic subtype allowed

                    -  Core biopsies are acceptable provided they contain adequate tissue for
                       primary diagnosis and immunophenotyping

                    -  Bone marrow biopsies as sole means of diagnosis are not allowed for
                       follicular lymphoma

               -  Hodgkin's lymphoma, meeting the following criteria:

                    -  Any WHO class histologic subtype allowed

                    -  Core biopsies are acceptable provided they contain adequate tissue for
                       primary diagnosis and immunophenotyping

               -  Multiple myeloma, meeting the following criteria:

                    -  Active disease requiring treatment (Durie-Salmon stages I, II, or III)

               -  Acute myeloid leukemia with documented control, defined as &lt; 10% bone marrow
                  blasts and no circulating blasts

               -  Acute lymphoblastic leukemia, meeting the following criteria:

                    -  In early first relapse or beyond OR in first complete remission and has 1 of
                       the following high-risk features:

                         -  t(9;22) or t(4;11)

                         -  WBC count &gt; 30,000/mm³ at presentation

                         -  Non-T-cell phenotype

                         -  More than 30 years of age

               -  Agnogenic myeloid metaplasia/myelofibrosis

                    -  Patients who are transfusion dependent or who have evolving myelodysplastic
                       or leukemic features or high-risk cytogenetic abnormalities are eligible

               -  Myelodysplastic syndromes (MDS) as defined by WHO criteria

          -  Meets 1 of the following criteria:

               -  Over 55 years of age

               -  Ineligible for busulfan-based therapy based on diminished organ function or poor
                  performance status

               -  Indolent and chemotherapy-responsive CLL, low-grade NHL, small lymphocytic
                  lymphoma, or PLL

          -  Patients who have undergone prior autologous stem cell transplantation are
             preferentially enrolled on clinical trial CALGB-100002, if available and patient is
             eligible

          -  HLA-matched or mismatched related donor or HLA-matched unrelated donor available

               -  HLA-identical sibling (6/6 or 9/10) (minimal serologic typing required for class
                  I [A, B]; molecular typing required for class II (DRB1))

               -  9/10 matched unrelated donor (MUD) (molecular analysis at HLA A, B, C, DRB1, and
                  DQB1 by high resolution typing required)

               -  5/6 MUD (molecular analysis at HLA A, B, and DRB1 required)

               -  No syngeneic donors

        PATIENT CHARACTERISTICS:

          -  Creatinine clearance ≥ 40 mL/min

          -  Bilirubin ≤ 3 times upper limit of normal (ULN)

          -  aspartate aminotransferase (AST) ≤ 3 times ULN

          -  Diffusing capacity of the lungs for carbon monoxide (DLCO) &gt; 40% with no symptomatic
             pulmonary disease

          -  Left ventricular ejection fraction (LVEF) ≥ 30% by multigated acquisition scan (MUGA)

          -  No uncontrolled diabetes mellitus or active serious infection

          -  No known hypersensitivity to Escherichia coli-derived products

          -  No HIV infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since prior chemotherapy, radiotherapy (except prophylactic cranial
             x-ray therapy), or surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas C. Shea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://unclineberger.org</url>
    <description>University of North Carolina (UNC) Lineberger Comprehensive Cancer Center</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2007</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>May 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>adult nasal type extranodal natural killer (NK)/T-cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with histologically confirmed hematologic malignancies, who were over the age of 55, or otherwise ineligible for more intensive busulfan-based therapy were enrolled on protocol Lineberger Comprehensive Cancer Center (LCCC) 0306 at the University of North Carolina.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Trial Participants</title>
          <description>All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Trial Participants</title>
          <description>All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="28" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Types</title>
          <description>Human leukocyte antigen (HLA) typing is used to match a recipient with a donor for bone marrow or cord blood transplant. Donor types are either HLA-matched related donor (MRD) or matched unrelated donor (MUD) or HLA-mismatched grafts.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>HLA-matched related donor (MRD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MUD or HLA-mismatched grafts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidity Index (CI)</title>
          <description>The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) was developed to identify relevant comorbidities in the allogeneic stem cell transplantation population and to enable risk assessment before allogeneic transplant. Comorbidities are given a a weighted score of 1 to 3 if present. The total score can range from 0 to 29, with higher numbers indicating more/worse comorbidities. The HCT-CI scores were further collapsed into 3 risk groups: 0 (low risk), 1 to 2 (intermediate risk), and 3 or more (high risk).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Risk Index (DRI)</title>
          <description>The DRI uses a combination of a ternary breakdown for disease type and a binary breakdown for remission status to assign patients to 1 of 4 risk categories that differ very significantly (statistically and clinically) with respect to overall survival (OS) and Progression free survival (PFS).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undetermined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Mortality</title>
        <description>Treatment related mortality for first 6 months. Defined as the number of treatment related deaths excluding deaths due to disease relapse.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Trial Participants</title>
            <description>All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality</title>
          <description>Treatment related mortality for first 6 months. Defined as the number of treatment related deaths excluding deaths due to disease relapse.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response at 6 and 12 Months Post-transplant</title>
        <time_frame>6 and 12 months</time_frame>
        <population>Complete response was not calculated at 6 and 12 months because the majority of patients had complete response at the time of transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>All Trial Participants</title>
            <description>All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response at 6 and 12 Months Post-transplant</title>
          <population>Complete response was not calculated at 6 and 12 months because the majority of patients had complete response at the time of transplant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete or Mixed Donor Chimerism at 30, 60, and 90 Days Post-transplant</title>
        <description>Complete chimerism is defined as 100% donor cells detected, suggesting complete hematopoietic replacement. Mixed donor chimerism means host cells are detected in particular cells like lymphocytes. Five to 90% donor cells set the criteria for mixed chimerism (MC).
Chimerism was not tabulated on day 30.</description>
        <time_frame>Days 30, 60, and 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 60</title>
            <description>60 days post-transplant</description>
          </group>
          <group group_id="O2">
            <title>Day 90</title>
            <description>90 days post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Complete or Mixed Donor Chimerism at 30, 60, and 90 Days Post-transplant</title>
          <description>Complete chimerism is defined as 100% donor cells detected, suggesting complete hematopoietic replacement. Mixed donor chimerism means host cells are detected in particular cells like lymphocytes. Five to 90% donor cells set the criteria for mixed chimerism (MC).
Chimerism was not tabulated on day 30.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Donor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Donor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Disease-free Survival</title>
        <description>The length of time post-transplant that the patient survives without any signs or symptoms of that cancer.</description>
        <time_frame>Year 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Trial Participants</title>
            <description>All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Disease-free Survival</title>
          <description>The length of time post-transplant that the patient survives without any signs or symptoms of that cancer.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft-vs-host Disease at 6 Months Post-transplant</title>
        <description>Graft-vs-host disease (GVHD) can be mild, moderate or severe depending on the differences in tissue type between patient and donor. Its symptoms can include:
Rashes, which include burning and redness, that erupt on the palms or soles and may spread to the trunk and eventually to the entire body
Blistering, causing the exposed skin surface to flake off in severe cases
Nausea, vomiting, abdominal cramps, diarrhea and loss of appetite, which can indicate that the gastrointestinal (digestive) tract is affected
Jaundice, or a yellowing of the skin, which can indicate liver damage
Excessive dryness of the mouth and throat, leading to ulcers
Dryness of the lungs, vagina and other surfaces
Acute GVHD - Can occur soon after the transplanted cells begin to appear in the recipient. Acute GVHD ranges from mild, moderate or severe, and can be life-threatening if its effects are not controlled.
Extensive chronic GVHD - Usually occurs at about three months post-transplant.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Trial Participants</title>
            <description>All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Graft-vs-host Disease at 6 Months Post-transplant</title>
          <description>Graft-vs-host disease (GVHD) can be mild, moderate or severe depending on the differences in tissue type between patient and donor. Its symptoms can include:
Rashes, which include burning and redness, that erupt on the palms or soles and may spread to the trunk and eventually to the entire body
Blistering, causing the exposed skin surface to flake off in severe cases
Nausea, vomiting, abdominal cramps, diarrhea and loss of appetite, which can indicate that the gastrointestinal (digestive) tract is affected
Jaundice, or a yellowing of the skin, which can indicate liver damage
Excessive dryness of the mouth and throat, leading to ulcers
Dryness of the lungs, vagina and other surfaces
Acute GVHD - Can occur soon after the transplanted cells begin to appear in the recipient. Acute GVHD ranges from mild, moderate or severe, and can be life-threatening if its effects are not controlled.
Extensive chronic GVHD - Usually occurs at about three months post-transplant.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extensive Chronic GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Trial Participants</title>
          <description>All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>graft failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Graft vs host disease grade 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>elevated lipase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>toxic epidermal nectrolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>liver toxicity/hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CMV viremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>CMV pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>BK viruria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>fungal pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>bronchiolitis obliterans organizing pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>EBV viremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>nocardia pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>subdural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Per the protocol, non-serious adverse events were not captured as this was a high-dose transplant study and grades 1,2, and 3 adverse events were expected. No unexpected toxicities were seen beyond those reported in the Serious Adverse Event section.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Thomas Shea</name_or_title>
      <organization>UNC Lineberger Comprehensive Cancer Center</organization>
      <phone>919-966-7746</phone>
      <email>tom_shea@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

